The year in gout: 2012-2013: A walk through the 2012 ACR gout treatment guidelines

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue 3, 2013, Pages 189-193

  Crittenden, Daria B ^a   Pillinger, Michael H ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOTROPIN; GLUCOCORTICOID; METHYLPREDNISOLONE; PEGLOTICASE; PREDNISONE; PROBENECID; TRIAMCINOLONE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIET; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EXERCISE; GOUT; HUMAN; HYDRATION; PRACTICE GUIDELINE; SMOKING CESSATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; UROLITHIASIS;

BENCHMARKING; EVIDENCE-BASED MEDICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84886562108     PISSN: 23284633     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41.
2. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679-687. e1.
3. Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011 Feb;124(2):155-63.
4. Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2013 Jan 12. [Epub ahead of print]
5. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007 Aug;116(8):894-900.
6. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006 Jul;22(7):1381-9.
7. Lynch W, Chan W, Kleinman N, et al. Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks. Popul Health Manag. 2013 Apr;16(2):138-45.
8. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006 Apr;12(2):61-5.
9. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012 Sep;71(9):1490-5.
10. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46.
11. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61.
12. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidencebased colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug;63(8):2226-37.
13. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1312-24.
14. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan;47(1):51-9.
15. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013 Jan;125(1):106-14.
16. Jansen TL, et al. International position paper on febuxostat. Clin Rheumatol. 2010 Aug;29(8):835-40.